Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study

Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 Leongamornlert, 2012, Germline BRCA1 mutations increase prostate cancer risk, Br J Cancer, 106, 1697, 10.1038/bjc.2012.146 Thompson, 2002, Cancer incidence in BRCA1 mutation carriers, J Natl Cancer Inst, 94, 1358, 10.1093/jnci/94.18.1358 1999, Cancer risks in BRCA2 mutation carriers, J Natl Cancer Inst, 91, 1310, 10.1093/jnci/91.15.1310 Kote-Jarai, 2011, BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients, Br J Cancer, 105, 1230, 10.1038/bjc.2011.383 van Asperen, 2005, Cancer risks in BRCA2 families: estimates for sites other than breast and ovary, J Med Genet, 42, 711, 10.1136/jmg.2004.028829 Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol, 31, 1748, 10.1200/JCO.2012.43.1882 Edwards, 2010, Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis, Br J Cancer, 103, 918, 10.1038/sj.bjc.6605822 Gallagher, 2010, Germline BRCA mutations denote a clinicopathologic subset of prostate cancer, Clin Cancer Res, 16, 2115, 10.1158/1078-0432.CCR-09-2871 Mitra, 2008, Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype, Br J Cancer, 98, 502, 10.1038/sj.bjc.6604132 Thorne, 2011, Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families, Cancer Prev Res, 4, 1002, 10.1158/1940-6207.CAPR-10-0397 Tryggvadottir, 2007, Prostate cancer progression and survival in BRCA2 mutation carriers, J Natl Cancer Inst, 99, 929, 10.1093/jnci/djm005 Giusti, 2003, A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology, J Med Genet, 40, 787, 10.1136/jmg.40.10.787 Andriole, 2012, Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up, J Natl Cancer Inst, 104, 125, 10.1093/jnci/djr500 Schroder, 2012, Prostate-cancer mortality at 11 years of follow-up, N Engl J Med, 366, 981, 10.1056/NEJMoa1113135 Catalona, 2002, Screening for prostate cancer in high risk populations, J Urol, 168, 1980, 10.1016/S0022-5347(05)64276-0 McWhorter, 1992, A screening study of prostate cancer in high risk families, J Urol, 148, 826, 10.1016/S0022-5347(17)36733-2 Neuhausen, 1997, Familial prostate cancer studies in Utah, Br J Urol, 79, 15, 10.1111/j.1464-410X.1997.tb00796.x Bunker, 2002, High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey, Cancer Epidemiol Biomarkers Prev, 11, 726 Kiemeney, 2008, Screening for prostate cancer in Dutch hereditary prostate cancer families, Int J Cancer, 122, 871, 10.1002/ijc.23165 Makinen, 2002, Family history and prostate cancer screening with prostate-specific antigen, J Clin Oncol, 20, 2658, 10.1200/JCO.2002.05.006 Matikainen, 1999, Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families, Clin Cancer Res, 5, 1275 Narod, 1995, The impact of family history on early detection of prostate cancer, Nat Med, 1, 99, 10.1038/nm0295-99 Sartor, 1996, Early detection of prostate cancer in African-American men with an increased familial risk of disease, J La State Med Soc, 148, 179 Uzzo, 2003, Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination, Urology, 61, 754, 10.1016/S0090-4295(02)02524-4 Valeri, 2002, Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives, J Urol, 168, 483, 10.1016/S0022-5347(05)64663-0 Mitra, 2011, Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study, BJU Int, 107, 28, 10.1111/j.1464-410X.2010.09648.x Mitra, 2007, A review of targeted screening for prostate cancer: introducing the IMPACT study, BJU Int, 99, 1350, 10.1111/j.1464-410X.2007.06759.x Haiman, 2013, Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations, J Natl Cancer Inst, 105, 237, 10.1093/jnci/djs486 Vickers, 2010, Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication, J Clin Oncol, 28, 2493, 10.1200/JCO.2009.24.1968 D’Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, 969, 10.1001/jama.280.11.969 Epstein, 2005, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, Am J Surg Pathol, 29, 1228, 10.1097/01.pas.0000173646.99337.b1 Berney, 2007, Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading, BJU Int, 100, 1240, 10.1111/j.1464-410X.2007.07199.x 2008 Schroder, 2009, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 1320, 10.1056/NEJMoa0810084 Andriole, 2009, Mortality results from a randomized prostate-cancer screening trial, N Engl J Med, 360, 1310, 10.1056/NEJMoa0810696 Pinsky, 2005, Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial, J Urol, 173, 746, 10.1097/01.ju.0000152697.25708.71 Dickinson, 2013, Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway, Urol Oncol, 31, 281, 10.1016/j.urolonc.2012.02.004 Khan, 2003, Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml, J Urol, 170, 723, 10.1097/01.ju.0000086940.10392.93 Verhamme, 2002, Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the Triumph project, Eur Urol, 42, 323, 10.1016/S0302-2838(02)00354-8 Nam, 2013, Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy, J Urol, 189, S12, 10.1016/j.juro.2012.11.015 Rosario, 2012, Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study, BMJ, 344, d7894, 10.1136/bmj.d7894 Hoedemaeker, 2001, Pathologic features of prostate cancer found at population-based screening with a four-year interval, J Natl Cancer Inst, 93, 1153, 10.1093/jnci/93.15.1153 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, editors. Globocan 2008: cancer incidence and mortality worldwide. IARC CancerBase no. 10. International Agency for Research on Cancer Web site. http://globocan.iarc.fr/factsheets/cancers/prostate.asp. Accessed January 3, 2013.